Literature DB >> 23064867

[Histopathology reports of findings of prostate needle biopsies. Individual treatment].

I Damjanoski1, J Müller, T J Schnöller, R Küfer, L Rinnab.   

Abstract

OBJECTIVES: This survey-based study examined which information urologists extract from prostate needle biopsy reports and what is needed for clinical management of prostate cancer patients.
MATERIAL AND METHODS: A questionnaire was developed to investigate several topics related to prostate cancer biopsies and four different clinical situations were explored separately, depending on whether the urologist intended a curative or palliative treatment.
RESULTS: A total of 95 out of 282 (33 %) urologists responded to the questionnaire and returned anonymous responses. On average the participants had a professional career of 13 years (range 6 months to 38 years), 22 (23 %) urologists performed radical prostatectomy, 73 (77 %) were not surgically active, 55 (58 %) took 10-12 scores within the framework of the proposed first biopsy setting, 32 (34 %) took 6-8 scores and 6 (6 %) > 12 scores. Urologists with a professional career <15 years took significantly more biopsies. The primary and secondary Gleason patterns were required for only 36 (38 %) respondents to make treatment decisions. In prostate needle biopsies containing only a single focus of prostate cancer only 44 (48 %) of the respondents would request a Gleason score if not provided in the initial report. In addition to the Gleason score other information used by urologists to make treatment decisions included perineural invasion (60 %), periprostatic infiltration (57 %), extraprostatic spread (57 %) and the percentage of core involvement by cancer (13 %). Interestingly, in biopsies with multiple positive cores from separate locations 84 out of 95 urologists (88 %) used the highest Gleason grade to determine the treatment plan. The term atypical small acinar proliferation (ASAP) was uniformly considered sufficient to retake biopsies by 44 % (42/92) of urologists and only 53 % (49/92) of urologists performed rebiopsies in the case of high grade prostatic intraepithelial neoplasia (PIN).
CONCLUSION: In this sample of 95 urologists there was high variability in the way clinicians used prostate needle biopsy pathology reports. The results of this survey underline that improved communication between urologists and pathologists is necessary.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23064867     DOI: 10.1007/s00120-012-3008-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  46 in total

1.  Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.

Authors:  Leon Sun; Judd W Moul; James M Hotaling; Edward Rampersaud; Phillipp Dahm; Cary Robertson; Nicholas Fitzsimons; David Albala; Thomas J Polascik
Journal:  BJU Int       Date:  2007-01-19       Impact factor: 5.588

Review 2.  Prostate biopsy: who, how and when. An update.

Authors:  Bob Djavan; Shirin Milani; Mesut Remzi
Journal:  Can J Urol       Date:  2005-02       Impact factor: 1.344

3.  Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project.

Authors:  Alexandre E Pelzer; Jasmin Bektic; Andreas P Berger; Ethan J Halpern; Florian Koppelstätter; Andrea Klauser; Peter Rehder; Wolfgang Horninger; Georg Bartsch; Ferdinand Frauscher
Journal:  Eur Urol       Date:  2005-08-10       Impact factor: 20.096

4.  The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer.

Authors:  J Endrizzi; T Seay
Journal:  BJU Int       Date:  2000-04       Impact factor: 5.588

5.  FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies.

Authors:  M K Werner; P Aschoff; M Reimold; C Pfannenberg
Journal:  Br J Radiol       Date:  2011-03       Impact factor: 3.039

Review 6.  [Value of positron emission tomography in urological neoplasms: more form than substance?].

Authors:  J Müller; M Schrader; A J Schrader; M Höpfner; F Zengerling
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

7.  Prediction of perineural invasion and its prognostic value in patients with prostate cancer.

Authors:  Jun Taik Lee; Seungsoo Lee; Chang Jin Yun; Byung Joo Jeon; Jung Man Kim; Hong Koo Ha; Wan Lee; Moon Kee Chung
Journal:  Korean J Urol       Date:  2010-11-17

8.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

Authors:  Gerald Andriole; David Bostwick; Otis Brawley; Leonard Gomella; Michael Marberger; Donald Tindall; Sharon Breed; Matt Somerville; Roger Rittmaster
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

9.  Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?

Authors:  Mark A Rubin; Tarek A Bismar; Sarah Curtis; James E Montie
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

Review 10.  Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Urol       Date:  2009-02-26       Impact factor: 7.450

View more
  1 in total

1.  [Documentation quality of histopathology reports of prostate needle biopsies: a snapshot].

Authors:  S Biesterfeld
Journal:  Urologe A       Date:  2014-11       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.